Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
11.
Curr Allergy Asthma Rep ; 14(10): 463, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25149165

RESUMO

Systemic contact dermatitis (SCD), a cutaneous reaction that is a direct manifestation of systemic exposure to a known allergen in a sensitized individual, has been increasingly recognized as a cause of persistent cutaneous contact dermatitis that is refractory to conventional therapies. While SCD in response to drugs has been described well in the literature, SCD to allergens in common foodstuffs is a less well-articulated phenomenon. Several foods that are universally consumed throughout the world contain potent allergens including nickel, balsam of Peru, trace metals, urushiol, and sesquiterpene lactones as well as a host of others that may cause a distinctive clinical picture. In this review article, the authors review the typical presentation and prevalence of SCD to foods, pathophysiology, the most common offensive ingestible food allergens, several appropriate diets, and effectiveness of dietary avoidance for situations in which SCD is suspected.


Assuntos
Alérgenos/efeitos adversos , Bálsamos/efeitos adversos , Dermatite Alérgica de Contato/etiologia , Hipersensibilidade Alimentar/etiologia , Níquel/efeitos adversos , Oligoelementos/efeitos adversos , Dermatite Alérgica de Contato/diagnóstico , Dermatite Alérgica de Contato/dietoterapia , Dermatite Alérgica de Contato/fisiopatologia , Hipersensibilidade Alimentar/diagnóstico , Hipersensibilidade Alimentar/dietoterapia , Hipersensibilidade Alimentar/fisiopatologia , Humanos
14.
JAMA Dermatol ; 2024 Sep 11.
Artigo em Inglês | MEDLINE | ID: mdl-39259524

RESUMO

This Viewpoint discusses the pros and cons of cost-saving prescription drug platforms in dermatology.

15.
17.
Expert Rev Hematol ; 10(2): 111-121, 2017 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-27998183

RESUMO

INTRODUCTION: CTCL are rare neoplasms. Optimal care requires integrated use of diagnostic and treatment modalities spanning multiple specialties. Current instruments for patient risk stratification and disease measurement across all anatomical compartments are suboptimal. A common treatment dichotomy between early (Dermatology) and advanced stage (Hematology-Oncology) has hindered accrual of long term outcome data. Thus, important facts about natural history, such as frequency and determinants of stage progression, and the impact of specific treatment modalities on these endpoints, are not known. Areas covered: One of the most important decisions in the management of CTCL is when to start systemic therapy and what agents to use. This review provides background information to understand why systemic therapy is needed and what goals are currently achievable. Expert commentary: Risk-adapted approaches, based on better knowledge of host and tumor biology, and more accurate disease measurement tools are needed to optimize the use of specific systemic therapies.


Assuntos
Linfoma Cutâneo de Células T/terapia , Pesquisa Biomédica , Tomada de Decisão Clínica , Terapia Combinada , Gerenciamento Clínico , Humanos , Linfoma Cutâneo de Células T/diagnóstico , Linfoma Cutâneo de Células T/etiologia , Linfoma Cutâneo de Células T/mortalidade , Estadiamento de Neoplasias , Medição de Risco , Padrão de Cuidado , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA